Retatrutide Explained: The Triple Agonist Changing Weight Loss | Amanda Curtis NP

By Amanda Curtis, MSN, APRN, FNP-BC — Owner & Nurse Practitioner, Aura Wellness & Aesthetics

If you follow the world of medically supervised weight loss, you have probably heard of semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). Retatrutide is the next step — and the clinical trial data is unlike anything we have seen before. Here is a plain-English breakdown of what it is, how it works, and why I am paying close attention to it.

What is retatrutide?

Retatrutide is a triple receptor agonist — it activates three receptors simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. That glucagon piece is what separates it from tirzepatide, which targets only GLP-1 and GIP.

Think of it as tirzepatide 3.0. Each receptor adds a distinct metabolic lever, and together they produce effects no single-agonist or dual-agonist drug has matched in trials to date.

The triple-receptor mechanism — what each receptor does

GLP-1 receptor: Slows gastric emptying, reduces appetite signaling in the brain, and improves insulin sensitivity. This is the mechanism behind semaglutide.

GIP receptor: Amplifies insulin release after eating and plays a role in fat storage and retrieval. Adding GIP to GLP-1 is what made tirzepatide more effective than semaglutide alone.

Glucagon receptor: This is where retatrutide goes further. Glucagon activation increases thermogenesis — your basal resting metabolic rate. In plain English: your body burns more calories at rest. It also directly stimulates the liver to reduce fat accumulation, which is relevant for people with fatty liver disease (hepatic steatosis).

What the Triumph trial data shows

Retatrutide is currently in Phase 3 clinical trials called the Triumph trials (1-4), with results expected by the end of 2026. The Phase 2 data was striking: participants on the highest dose experienced a mean weight loss of 28.7% at 68 weeks — the highest ever recorded in any Phase 3-scale clinical trial. For context, semaglutide averages around 15-17% and tirzepatide around 20-22%.

Beyond weight, early data also suggests retatrutide may:

• Meaningfully reduce hepatic steatosis (fatty liver)
• Improve outcomes in patients with sleep apnea and cardiovascular risk
• Reduce pain and inflammation associated with knee osteoarthritis
• Increase basal metabolic rate through direct thermogenic effects

How is it different from tirzepatide?

Both drugs target GLP-1 and GIP. The key difference is the third receptor. Tirzepatide does not activate the glucagon receptor — which means it does not have the same thermogenic or direct hepatic effect. For patients whose primary concern is metabolic syndrome, fatty liver, or who have plateaued on tirzepatide, retatrutide may eventually offer a meaningful step up.

That said, retatrutide is not yet FDA-approved. Phase 3 results will determine whether the weight loss efficacy translates at scale and what the full safety profile looks like.

Who might benefit most?

Based on the mechanism and early trial data, retatrutide may be especially interesting for patients with obesity with metabolic complications (fatty liver, insulin resistance, cardiovascular risk), obesity-related sleep apnea, knee osteoarthritis exacerbated by weight, or patients who have tried GLP-1 or dual-agonist therapy and want to understand what is coming next.

What I tell patients right now

Retatrutide is not available for prescription yet — we are watching the Triumph trial data closely. What it represents is a genuine evolution in how we approach metabolic health, not just another weight-loss drug. The thermogenic component alone makes it mechanistically distinct from everything currently on the market.

If you are currently on semaglutide or tirzepatide and wondering what the next chapter looks like, this is it. If you are just starting to explore medically supervised weight loss, this is a great time to get your metabolic baseline established so you are ready when the next generation of therapies arrives.

Let us talk about your options

At Aura Wellness & Aesthetics, we stay current on emerging therapies so you do not have to. If you want to discuss medically supervised weight loss — what is available now and what is on the horizon — we would love to hear from you.

📍 946 N Loop 1604 W, Suite 118 | San Antonio, TX
📞 210-981-6460

For educational purposes only. Retatrutide is not FDA-approved. Consult your healthcare provider before starting any medication or peptide therapy.

This article is educational only and is not medical advice; it is not intended to diagnose, treat, cure, or prevent any disease. Compounded medications and peptides are prescribed only when clinically appropriate, through FDA-registered 503A pharmacies.